If you're implying in your last sentence that the same can happen with SFOR before its r/s, I couldn't disagree more. For one thing, DSS shareholders will be getting shares in Impact Biomedical as a dividend after their r /s. For another, the management structure in each company is dissimilar. Chan is sort of reminding me of the way that Buffett built his empire, Kay does not.

Without an announcement of revenue or some other important positive development, there's little reason to hope for a similar run up. Much less a sustained higher lever of share price. With such an announcement, hope will spring eternal.